PMID- 36721897
OWN - NLM
STAT- MEDLINE
DCOM- 20230202
LR  - 20231213
IS  - 1531-703X (Electronic)
IS  - 1040-8746 (Linking)
VI  - 35
IP  - 2
DP  - 2023 Mar 1
TI  - A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in 
      treating patients with different types of thyroid cancer: how to choose drugs 
      appropriately?
PG  - 132-144
LID - 10.1097/CCO.0000000000000924 [doi]
AB  - PURPOSE OF REVIEW: Because the high risk of death and poor prognosis of patients 
      with refractory thyroid cancer (TC), studies related to tyrosine kinase 
      inhibitors (TKIs) in treating different types of refractory TC have gradually 
      attracted attention. Thus, we conducted a meta-analysis of published randomized 
      controlled trials and single-arm trials to evaluate tyrosine kinase inhibitors' 
      efficacy and safety profile treatment in TC patients. RECENT FINDINGS: The 
      studies of 29 in 287 met the criteria, 9 were randomized controlled trials and 20 
      were single-arm trials, involving 11 TKIs (Apatinib, Anlotinib, Cabozantinib, 
      Imatinib, Lenvatinib, Motesanib, Pazopanib, Sorafenib, Sunitinib, Vandetanib, 
      Vemurafenib). Treatment with TKIs significantly improved progression-free 
      survival [hazard ratio [HR] 0.34 (95% confidence interval [CI]: 0.24, 0.48), 
      P < 0.00001] and overall survival [OS] [HR 0.76, (95% CI: 0.64, 0.91), P = 0.003] 
      in randomized controlled trials, but adverse events (AEs) were higher than those 
      in the control group (P < 0.00001). The result of the objective response rate 
      (ORR) in single-arm trials was statistically significant [odds ratio [OR] 0.49 
      (95% CI: 0.32, 0.75), P = 0.001]. SUMMARY: TKIs significantly prolonged 
      progression-free survival and OS or improved ORR in patients with different types 
      of TC (P < 0.01). Our recommendation is to select appropriate TKIs to treat 
      different types of TC patients, and to prevent and manage drug-related AEs after 
      using TKIs.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Su, Jingyang
AU  - Su J
AD  - Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese 
      Medical University.
FAU - Lu, Jinhua
AU  - Lu J
AD  - Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese 
      Medical University.
FAU - Zhang, Jialin
AU  - Zhang J
AD  - Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese 
      Medical University.
FAU - Wang, Menglei
AU  - Wang M
AD  - Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese 
      Medical University.
FAU - Yan, Jiang
AU  - Yan J
AD  - Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese 
      Medical University.
FAU - Lin, Shengyou
AU  - Lin S
AD  - Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical 
      University, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221228
PL  - United States
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
RN  - 0 (Tyrosine Kinase Inhibitors)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Humans
MH  - *Tyrosine Kinase Inhibitors
MH  - *Thyroid Neoplasms/drug therapy
MH  - Sorafenib
MH  - Imatinib Mesylate
MH  - Progression-Free Survival
EDAT- 2023/02/02 06:00
MHDA- 2023/02/03 06:00
CRDT- 2023/02/01 02:03
PHST- 2023/02/01 02:03 [entrez]
PHST- 2023/02/02 06:00 [pubmed]
PHST- 2023/02/03 06:00 [medline]
AID - 00001622-202303000-00009 [pii]
AID - 10.1097/CCO.0000000000000924 [doi]
PST - ppublish
SO  - Curr Opin Oncol. 2023 Mar 1;35(2):132-144. doi: 10.1097/CCO.0000000000000924. 
      Epub 2022 Dec 28.